This week, the FDA granted priority review to Novartis’ innovator biologic, RTH258, brolucizumab. The vascular endothelial growth factor (VEGF) inhibitor is intended to treat wet age-related macular degeneration.
This week, the FDA granted priority review to Novartis’ innovator biologic, RTH258, brolucizumab. The biologic is intended to treat wet age-related macular degeneration (AMD), or neovascular AMD. Novartis said in an announcement that, if the drug is approved, it could launch as soon as the end of 2019.
Brolucizumab is a humanized single-chain antibody fragment with enhanced tissue penetration and rapid clearance from systemic circulation. The structure results in a small molecule, 26 kDa, that allows for the inhibition of all isoforms of vascular endothelial growth factor (VEGF). Single-chain antibodies have been shown elsewhere to be suitable for high, less frequent doses that result in lower systemic exposure, which means that the treatment has the potential to reduce the burden of injections for patients.
The application for the new biologic is based on phase 3 data from 2 prospective, randomized, double-masked multicenter studies, both of which had noninferiority to fellow anti-VEGF agent aflibercept (Eylea) as a primary endpoint. The head-to-head trials demonstrated that the proposed biologic was effective at week 48 and was noninferior to aflibercept.
In terms of a secondary endpoint, brolucizumab outperformed aflibercept; in both studies, significantly fewer patients treated with brolucizumab had disease activity, as well as retinal fluid, versus patients treated with aflibercept.
Novartis’ filing for the anti-VEGF agent comes as biosimilars for anti-VEGF therapies are advancing; Republic of Korea-based Alteogen has recently secured a process patent for its aflibercept biosimilar, which it says has better resilience to high temperatures and a longer shelf-life than the innovator drug. Momenta and Mylan have entered a phase 3 pivotal trial of a biosimilar aflibercept candidate as of August 2018. Additionally, Coherus BioSciences is advancing an aflibercept candidate and a ranibizumab candidate, referencing the anti-VEGF agent Lucentis. Xbrane Biopharma and Samsung Bioepis are also both working on biosimilars of ranibizumab.
Finally, the FDA has approved a biosimilar bevacizumab (referencing Avastin), under the brand name Mvasi. While bevacizumab does not carry an indication for the treatment of eye disorders, it is routinely used off-label as an alternative to other, more expensive anti-VEGF agents in ophthalmology.
It remains to be seen whether brolucizumab will be able to differentiate itself from a bevy of potentially cost-saving anti-VEFG biosimilars with its superiority in terms of retinal fluid and the benefit of less frequent injections. However, what is clear is that Regeneron, maker of the brand-name aflibercept, would feel significant pressure from both the market entry of biosimilars referencing its product and the launch of a novel competitor, particularly if Novartis chooses to launch its product at an attractive price.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.